| Primary |
| Hiv Infection |
82.2% |
| Drug Exposure During Pregnancy |
9.3% |
| Antibiotic Prophylaxis |
2.5% |
| Ecthyma |
1.7% |
| Human Immunodeficiency Virus Transmission |
1.7% |
| Prophylaxis |
1.7% |
| Fungal Infection |
0.8% |
|
| Viral Mutation Identified |
24.1% |
| Drug Abuse |
6.9% |
| Hepatomegaly |
6.9% |
| Portal Vein Thrombosis |
6.9% |
| Anaemia |
3.4% |
| Caesarean Section |
3.4% |
| Chronic Hepatic Failure |
3.4% |
| Drug Interaction |
3.4% |
| General Physical Health Deterioration |
3.4% |
| Hepatic Cirrhosis |
3.4% |
| Hepatic Failure |
3.4% |
| Lung Neoplasm Malignant |
3.4% |
| Nephrolithiasis |
3.4% |
| Portal Hypertension |
3.4% |
| Renal Impairment |
3.4% |
| Small For Dates Baby |
3.4% |
| Tachycardia |
3.4% |
| Therapy Non-responder |
3.4% |
| Vaginal Infection |
3.4% |
| Vomiting |
3.4% |
|
| Secondary |
| Hiv Infection |
46.5% |
| Drug Exposure During Pregnancy |
17.8% |
| Drug Use For Unknown Indication |
15.4% |
| Product Used For Unknown Indication |
4.1% |
| Acquired Immunodeficiency Syndrome |
3.8% |
| End Stage Aids |
3.6% |
| Hepatitis C |
1.4% |
| Systemic Antiviral Treatment |
1.3% |
| Gestational Diabetes |
1.2% |
| Antiretroviral Therapy |
0.7% |
| Depression |
0.6% |
| Antifungal Prophylaxis |
0.5% |
| Prophylaxis |
0.5% |
| Factor Viii Deficiency |
0.4% |
| Hiv Infection Cdc Category A3 |
0.4% |
| Hypertension |
0.4% |
| Insomnia |
0.4% |
| Liver Disorder |
0.4% |
| Opportunistic Infection Prophylaxis |
0.4% |
| Drug Withdrawal Maintenance Therapy |
0.3% |
|
| Umbilical Cord Abnormality |
19.4% |
| Cytolytic Hepatitis |
10.2% |
| Premature Labour |
10.2% |
| Viral Mutation Identified |
10.2% |
| Gastrointestinal Malformation |
6.5% |
| Weight Decreased |
5.6% |
| Tethered Cord Syndrome |
4.6% |
| Exomphalos |
3.7% |
| Pruritus |
3.7% |
| Renal Failure Chronic |
3.7% |
| Hepatotoxicity |
2.8% |
| Premature Baby |
2.8% |
| Soft Tissue Haemorrhage |
2.8% |
| Vomiting |
2.8% |
| Congenital Aplastic Anaemia |
1.9% |
| Drug Resistance |
1.9% |
| Hyperbilirubinaemia |
1.9% |
| Laryngeal Cancer |
1.9% |
| Liver Disorder |
1.9% |
| Myocardial Infarction |
1.9% |
|
| Concomitant |
| Hiv Infection |
64.3% |
| Drug Use For Unknown Indication |
16.7% |
| Antibiotic Prophylaxis |
3.5% |
| Medical Diet |
3.1% |
| Mycobacterium Avium Complex Infection |
1.2% |
| Pneumocystis Jiroveci Pneumonia |
1.2% |
| Decreased Appetite |
1.0% |
| Vitamin Supplementation |
1.0% |
| Mineral Supplementation |
1.0% |
| Hypertension |
0.9% |
| Prophylaxis |
0.9% |
| Depression |
0.8% |
| Antifungal Prophylaxis |
0.8% |
| Diabetes Mellitus Insulin-dependent |
0.8% |
| Candidiasis |
0.6% |
| Histiocytosis Haematophagic |
0.6% |
| Anaemia |
0.4% |
| Antiretroviral Therapy |
0.4% |
| Atypical Mycobacterial Infection |
0.4% |
| Diarrhoea Infectious |
0.4% |
|
| Death |
43.8% |
| Weight Decreased |
10.1% |
| Contusion |
6.9% |
| Vomiting |
5.1% |
| Hodgkin's Disease |
3.3% |
| Intracranial Aneurysm |
3.3% |
| Septic Shock |
3.3% |
| Sepsis |
2.9% |
| Hydrocephalus |
2.5% |
| Leukoencephalopathy |
2.5% |
| Meningeal Disorder |
2.2% |
| Disease Progression |
1.8% |
| Nephrotic Syndrome |
1.8% |
| Shock Haemorrhagic |
1.8% |
| Ascites |
1.4% |
| Cerebrovascular Accident |
1.4% |
| Drug Ineffective |
1.4% |
| Haemorrhage Intracranial |
1.4% |
| Lung Neoplasm |
1.4% |
| Peritonitis |
1.4% |
|
| Interacting |
| Hiv Infection |
50.0% |
| Drug Use For Unknown Indication |
30.0% |
| Acquired Immunodeficiency Syndrome |
10.0% |
| Epilepsy |
10.0% |
|
| Drug Interaction |
33.3% |
| Drug Level Decreased |
33.3% |
| Weight Decreased |
33.3% |
|
